Large gap with delayed quotes
|
Last quote
06/18/2026
-
02:00:00
|
Bid
06/17/2026 -
21:59:59
|
Bid Volume |
Ask
06/17/2026 -
21:59:59
|
Ask Volume |
|---|---|---|---|---|
|
53.09
+1.07
(
+2.06% )
|
53.11
|
1,100 |
53.12
|
1,300 |
Analysis date: 16.06.2026
Global Evaluation
Slightly negative
Slightly negative
The stock is classified in the slightly negative zone since 22.05.2026.
Interest
Weak
Weak
Two stars since 16.06.2026.
Earnings Rev Trend
Positive
Positive
Compared to seven weeks ago, the analysts have raised their earnings per share estimates. This positive trend began 05.05.2026 at a price of 52.38.
Evaluation
Strongly overvalued
Strongly overvalued
Based on its growth potential and our own criteria, we believe the share price is currently overvalued.
MT Tech Trend
Neutral
Neutral
The stock is currently trading close to its dividend-adjusted forty day moving average (changes between +1.75% and -1.75% are considered neutral). Prior to this, the stock traded below its moving average since 12.06.2026.
4wk Rel Perf
6.07%
6.07%
The four-week dividend-adjusted overperformance versus SP500 is 6.07%.
Sensibility
High
High
High, no change over 1 year.
Bear Market Factor
Middle
Middle
On average, the stock is likely to decline with the index.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 4.57%.
Mkt Cap in $bn
5.07
5.07
With a market capitalization between $2 & $8bn, CRISPR THERAPEUTICS is considered a mid-cap stock.
G/PE Ratio
0.50
0.50
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) below 0.6 indicates that investors must pay a substantial premium for the estimated growth potential: >50% premium.
LT P/E
-20.30
-20.30
The estimated PE is negative: the financial analysts' earnings estimates forecast a loss.
LT Growth
10.15%
10.15%
The annualized growth estimate is for the current year to 2028.
Avg. Nb analysts
19
19
Over the last seven weeks, an average of 19 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
153
153
For 1% of index variation, the stock varies on average by 1.53%.
Correlation
0.33
0.33
Stock movements are strongly independent of index variations.
Value at Risk
24.14
24.14
The value at risk is estimated at USD 24.14. The risk is therefore 46.40%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
08.09.2020
08.09.2020